Single User License
INR 747880
Site License
INR 1495760
Corporate User License
INR 2243640

Service Tax Additional

select a format
Price

Single User License
USD 10995
Site License
USD 21990
Corporate User License
USD 32985

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


PharmaPoint: Dyslipidemia-Global Drug Forecast Market Analysis to 2023

PharmaPoint: Dyslipidemia-Global Drug Forecast Market Analysis to 2023


  Request for Sample Report

Executive Summary

PharmaPoint: Dyslipidemia-Global Drug Forecast and Market Analysis to 2023

GlobalData estimates that the total market size for the 8MM in 2013 was USD 15.4bn, comprised of USD 11.0bn in branded drug sales (72%) and USD 4.4bn in generic sales (28%). GlobalData expects that the dyslipidemia drug market will grow at a CAGR of 9.4% over the ten year forecast period, resulting in a market value of USD 37.9bn by 2023, of which 71% will be attributed to branded drug sales (USD 26.9bn) and 29% to generic drug sales (USD 11.0bn). The current dyslipidemia market is dominated by the statins, the revolutionary drugs that reduce low-density lipoprotein cholesterol (LDL-C) and that have been proven to reduce the risk of cardiovascular events such as heart attack and stroke. Other major lipid-modulating drugs, such as Zetia (ezetimibe), the fibrates, bile acid sequestrants, omega-3 fish oil agents, and rare-disease therapies comprise the remainder of the current dyslipidemia space. The launch of the proprotein convertase subtilisin/kexin type 9 (PCSK9) biologics and the cholesteryl ester transfer protein (CETP) inhibitors will reshape the sales landscape of the dyslipidemia market moving forward.

Highlights

Key Questions Answered

How will major clinical trials of currently marketed therapies impact the future of the dyslipidemia market? Particular attention will be given to the HPS2-THRIVE and IMPROVE-IT Phase III studies of niacin and Zetia (ezetimibe).

What role will statins play in the future of the dyslipidemia market?

What are the clinical, regulatory, and commercial prospects of the proprotein convertase subtilisin/kexin type 9 monoclonal antibodies (PCSK9 mAbs) from Amgen, Sanofi/Regeneron, and Pfizer and the cholesteryl ester transfer protein (CETP) inhibitors from Eli Lilly, Merck, and Dezima Pharma?

How will novel lipid-modulating agents, such as Esperion Therapeutic's ETC-1002 and Cerenis Therapeutic's CER-001, impact the dynamics of the dyslipidemia market?

What are the key market drivers, barriers, and unmet needs that remain unaddressed by currently marketed therapies? What will remain unaddressed by the current dyslipidemia pipeline?

Key Findings

The highest-impact driver of the dyslipidemia market will be the launch of the PCSK9 inhibitors, human monoclonal antibody biologics that will be used to treat high LDL-C in addition to statins. Therapeutic novelty combined with biologic pricing will make the PCSK9s the largest contributors to dyslipidemia market growth, even if their use is reserved for niche or high-risk cases.

The CETP inhibitors in the late-stage pipeline have the potential to bring a novel tool to bear against high LDL-C and low HDL-C. However, their success at the regulatory level will depend heavily on their success in major Phase III cardiovascular outcomes trials, making the CETPs the wild-cards of the dyslipidemia pipeline.

Due to the maturity of the current dyslipidemia market, new therapies will need to exploit novel mechanisms of action and/or target orphan drug targets and are more likely to be utilized as add-on therapies to existing treatments. There is a unique opportunity in the familial hypercholesterolemia arena, where effective LDL-C lowering therapies are needed that exhibit clean safety/side-effect profiles.

Scope

Overview of dyslipidemia, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

Annualized dyslipidemia therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2013 and forecast for ten years to 2023.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications for the dyslipidemia therapeutics market.

Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.

Analysis of the current and future market competition in the global dyslipidemia therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons To Buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.

Develop business strategies by understanding the trends shaping and driving the dyslipidemia therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the dyslipidemia therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Track drug sales in the 8MM dyslipidemia therapeutics market from 2013-2023.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

1 Table of Contents

1 Table of Contents 11

1.1 List of Tables 17

1.2 List of Figures 24

2 Introduction 26

2.1 Catalyst 26

2.2 Related Reports 28

2.3 Upcoming Related Reports 28

3 Disease Overview 29

3.1 Etiology and Pathophysiology 29

3.1.1 Etiology 29

3.1.2 Pathophysiology 31

3.2 Symptoms 35

3.3 Prognosis 35

3.4 Quality of Life 35

4 Epidemiology 36

4.1 Risk Factors and Comorbidities 36

4.2 Global and Historical Trends 37

4.2.1 US 38

4.2.2 5EU 38

4.2.3 Asia 40

4.3 Forecast Methodology 41

4.3.1 Sources Used 49

4.3.2 Forecast Assumptions and Methods 55

4.3.3 Sources Not Used 81

4.4 Prevalent Cases of Dyslipidemia 82

4.4.1 Total Prevalent Cases of Dyslipidemia 82

4.4.2 Age-Specific Total Prevalent Cases of Dyslipidemia 83

4.4.3 Sex-Specific Total Prevalent Cases of Dyslipidemia 85

4.4.4 Age-Standardized Total Prevalence of Dyslipidemia 87

4.5 Epidemiological Forecast for Familial Hypercholesterolemia (2013-2023) 88

4.5.1 Total Prevalent Cases of Familial Hypercholesterolemia 88

4.6 Epidemiological Forecast for Increased LDL-C (2013-2023) 89

4.6.1 Total Prevalent Cases of Increased LDL-C 89

4.6.2 Age-Specific Total Prevalent Cases of Increased LDL-C 91

4.6.3 Sex-Specific Total Prevalent Cases of Increased LDL-C 93

4.6.4 Age-Standardized Total Prevalence of Increased LDL-C 95

4.7 Epidemiological Forecast for Very High TG (?500mg/dL) (2013-2023) 96

4.7.1 Total Prevalent Cases of Very High TG (?500mg/dL) 96

4.7.2 Age-Specific Total Prevalent Cases of Very High TG (?500mg/dL) 98

4.7.3 Sex-Specific Total Prevalent Cases of Very High TG (?500mg/dL) 100

4.7.4 Age-Standardized Total Prevalence of Very High TG (?500mg/dL) 102

4.8 Discussion 103

4.8.1 Epidemiological Forecast Insight 103

4.8.2 Limitations of the Analysis 104

4.8.3 Strengths of the Analysis 105

5 Disease Management 106

5.1 Diagnosis and Treatment Overview 106

5.1.1 Diagnosis 106

5.1.2 Treatment Guidelines and Leading Prescribed Drugs 108

5.1.3 Clinical Practice 111

5.2 US 113

5.3 France 117

5.4 Germany 119

5.5 Italy 122

5.6 Spain 125

5.7 UK 126

5.8 Japan 129

5.9 China 131

6 Competitive Assessment 134

6.1 Overview 134

6.2 Product Profiles-Major Brands 138

6.2.1 Statins 138

6.2.2 Zetia (ezetimibe) 158

6.2.3 Vytorin (simvastatin/ezetimibe) 167

6.2.4 Liptruzet (atorvastatin/ezetimibe) 171

6.2.5 Niaspan (niacin extended-release) 175

6.2.6 Kynamro (mipomersen sodium) 181

6.2.7 Juxtapid (lomitapide) 188

6.2.8 TriCor/Trilipix (fenofibrate/fenfibric acid) 193

6.2.9 Omega-3 Fatty Acids 198

6.2.10 Welchol (colesevelam HCl) and the Bile Acid Sequestrants 213

7 Unmet Need and Opportunity 219

7.1 Overview 219

7.2 LDL-C-Lowering Drugs for Statin-Intolerant and Statin-Refractory Patients 220

7.2.1 Unmet Need 220

7.2.2 Gap Analysis 221

7.2.3 Opportunity 222

7.3 Improved Diagnosis, Patient Education, and Long-term Compliance 223

7.3.1 Unmet Need 223

7.3.2 Gap Analysis 224

7.3.3 Opportunity 226

7.4 Therapies that Prevent or Reverse the Build-Up of Atherosclerotic Plaque 227

7.4.1 Unmet Need 227

7.4.2 Gap Analysis 228

7.4.3 Opportunity 229

7.5 Therapies for Patients with HoFH with Improved Side Effect Profiles 230

7.5.1 Unmet Need 230

7.5.2 Gap Analysis 231

7.5.3 Opportunity 232

8 Pipeline Assessment 233

8.1 Overview 233

8.2 Clinical Trial Mapping 237

8.2.1 Clinical Trials by Patient Population 237

8.3 Promising Drugs in Clinical Development 237

8.3.1 Alirocumab 237

8.3.2 Bococizumab 246

8.3.3 Evolocumab 251

8.3.4 Anacetrapib 260

8.3.5 Evacetrapib 268

8.3.6 TA-8995 (DEZ-001) 274

8.3.7 CER-001 280

8.3.8 ETC-1002 286

8.4 Other Drugs in Development 294

9 Current and Future Players 295

9.1 Overview 295

9.2 Trends in Corporate Strategy 300

9.3 Company Profiles 302

9.3.1 AbbVie 302

9.3.2 Aegerion Pharmaceuticals, Inc. 304

9.3.3 Amarin 306

9.3.4 Amgen 308

9.3.5 AstraZeneca 310

9.3.6 Cerenis Therapeutics Inc. 313

9.3.7 Daiichi Sankyo 315

9.3.8 Dezima Pharma 317

9.3.9 Eli Lilly 319

9.3.10 Esperion Therapeutics, Inc. 322

9.3.11 Genzyme 324

9.3.12 GlaxoSmithKline 326

9.3.13 Merck & Co. 328

9.3.14 Pfizer 331

9.3.15 Regeneron Pharmaceuticals, Inc. 333

9.3.16 Sanofi 335

10 Market Outlook 339

10.1 Global Markets 339

10.1.1 Forecast 339

10.1.2 Drivers and Barriers-Global Issues 348

10.2 United States 351

10.2.1 Forecast 351

10.2.2 Key Events 356

10.2.3 Drivers and Barriers 357

10.3 5EU 359

10.3.1 Forecast 359

10.3.2 Key Events 367

10.3.3 Drivers and Barriers 368

10.4 Japan 371

10.4.1 Forecast 371

10.4.2 Key Events 374

10.4.3 Drivers and Barriers 375

10.5 China 377

10.5.1 Forecast 377

10.5.2 Key Events 381

10.5.3 Drivers and Barriers 381

11 Appendix 384

11.1 Bibliography 384

11.2 Abbreviations 412

11.3 Methodology 420

11.4 Forecasting Methodology 420

11.4.1 Diagnosed Dyslipidemia Patients 420

11.4.2 Percent Drug-Treated Patients 421

11.4.3 Drugs Included in Each Therapeutic Class 421

11.4.4 Launch and Patent Expiry Dates 422

11.4.5 General Pricing Assumptions 423

11.4.6 Individual Drug Assumptions 424

11.4.7 Generic Erosion 431

11.4.8 Pricing of Pipeline Agents 431

11.5 Physicians and Specialists Included in this Study 432

11.6 About the Authors 434

11.6.1 Analyst 434

11.6.2 Therapy Area Director 435

11.6.3 Epidemiologist 435

11.6.4 Global Head of Healthcare 436

11.7 About GlobalData 437

11.8 Disclaimer 437

1.2 List of Figures

Figure 1: 8MM, Total Prevalent Cases of Dyslipidemia, Both Sexes, Ages ?20 Years, N, 2013-2023 83

Figure 2: 8MM, Age-Specific Total Prevalent Cases of Dyslipidemia, Both Sexes, Ages ?20 Years, N, 2013 85

Figure 3: 8MM, Sex-Specific Total Prevalent Cases of Dyslipidemia, Ages ?20 Years, N, 2013 86

Figure 4: 8MM, Age-Standardized Total Prevalence of Dyslipidemia (%), Ages ?20 Years, by Sex, 2013 87

Figure 5: 8MM, Total Prevalent Cases of Familial Hypercholesterolemia, Both Sexes, Ages ?20 Years, N, 2013-2023 89

Figure 6: 8MM, Total Prevalent Cases of Increased LDL-C* (?115mg/dL to ?160mg/dL), Both Sexes, Ages ?20 Years, N, 2013-2023 91

Figure 7: 8MM, Age-Specific Total Prevalent Cases of Increased LDL-C* (?115mg/dL to ?160mg/dL), Both Sexes, Ages ?20 Years, N, 2013 93

Figure 8: 8MM, Sex-Specific Total Prevalent Cases of Increased LDL-C* (?115mg/dL to ?160mg/dL), Ages ?20 Years, N, 2013 95

Figure 9: 8MM, Age-Standardized Total Prevalence of Increased LDL-C (?115mg/dL to ?160mg/dL)* (%), Ages ?20 Years, by Sex, 2013 96

Figure 10: 8MM, Total Prevalent Cases of Very High TG (?500mg/dL), Both Sexes, Ages ?20 Years, N, 2013-2023 98

Figure 11: 8MM, Age-Specific Total Prevalent Cases of Very High TG (?500mg/dL), Both Sexes, Ages ?20 Years, N, 2013 100

Figure 12: 8MM, Sex-Specific Total Prevalent Cases of Very High TG (?500mg/dL), Ages ?20 Years, N, 2013 101

Figure 13: 8MM, Age-Standardized Total Prevalence of Very High TG (?500mg/dL) (%), Ages ?20 Years, by Sex, 2013 102

Figure 14: Competitive Assessment of Late-Stage Pipeline Agents in Dyslipidemia, 2013-2023 236

Figure 15: Dyslipidemia Therapeutics-Clinical Trials by Indication and Lipid Biomarker, 2014 237

Figure 16: Global Sales of Branded Products for Dyslipidemia by Company, 2013-2023 299

Figure 17: Company Portfolio Gap Analysis in Dyslipidemia, 2013-2023 300

Figure 18: Global Sales for Dyslipidemia by Country, 2013-2023 344

Figure 19: Global Sales for Dyslipidemia by Drug Class, 2013-2023 345

Figure 20: Global Sales Forecast for PCSK9 mAbs, 2015-2023 346

Figure 21: Projected Global Sales of Dyslipidemia Drugs by Year, 2013-2023 347

Figure 22: Sales for Dyslipidemia in the United States by Drug Class, 2013-2023 355

Figure 23: Composite Sales for Dyslipidemia in the 5EU by Drug Class, 2013-2023 362

Figure 24: Sales Breakdown for the 5EU Markets, 2013-2023 363

Figure 25: 5EU Country Sales, Segmented by Drug Class, 2013-2023 364

Figure 26: High-Selling* Drug Classes in the 5EU, Segmented by Country, 2013-2023 365

Figure 27: Low-Selling* Drug Classes in the 5EU, Segmented by Country, 2013-2023 366

Figure 28: Sales for Dyslipidemia in Japan by Drug Class, 2013-2023 373

Figure 29: Sales for Dyslipidemia in China by Drug Class, 2013-2023 380

1.1 List of Tables

Table 1: Dyslipidemia: Key Metrics in Eight Major Pharmaceutical Markets 29

Table 2: Common Secondary Causes of Dyslipidemia 31

Table 3: Risk Factors and Comorbidities for Dyslipidemia 37

Table 4: Overview of the Total Prevalence of Low HDL-C in the 5EU 40

Table 5: NCEP ATP III Classification of LDL-C, TG, and HDL-C 42

Table 6: Simon Broome Diagnostic Criteria for FH 43

Table 7: LDL-C Based Definition of FH 43

Table 8: Sources of Total Prevalence Data for FH in the 8MM 44

Table 9: Sources of Total Prevalence Data for Increased LDL-C in the 8MM 45

Table 10: Sources of Total Prevalence Data for High TG (?200mg/dL) in the 8MM 46

Table 11: Sources of Total Prevalence Data for Very High TG (?500mg/dL) in the 8MM 47

Table 12: Sources of Total Prevalence Data for Low HDL-C in the 8MM 48

Table 13: 8MM, Sources Not Used in the Epidemiological Analysis of Dyslipidemia 81

Table 14: 8MM, Total Prevalent Cases of Dyslipidemia, Both Sexes, Ages ?20 Years, N, 2013-2023 82

Table 15: 8MM, Age-Specific Total Prevalent Cases of Dyslipidemia, Both Sexes, N (Row %), 2013 84

Table 16: 8MM, Sex-Specific Total Prevalent Cases of Dyslipidemia, Ages ?20 Years, N (Row %), 2013 86

Table 17: 8MM, Total Prevalent Cases of Familial Hypercholesterolemia, Both Sexes, Ages ?20 Years, N, 2013-2023 88

Table 18: 8MM, Total Prevalent Cases of Increased LDL-C* (?115mg/dL to ?160mg/dL), Both Sexes, Ages ?20 Years, N, 2013-2023 90

Table 19: 8MM, Age-Specific Total Prevalent Cases of Increased LDL-C* (?115mg/dL to ?160mg/dL), Both Sexes, N (Row %), 2013 92

Table 20: 8MM, Sex-Specific Total Prevalent Cases of Increased LDL-C* (?115mg/dL to ?160mg/dL), Ages ?20 Years, N (Row %), 2013 94

Table 21: 8MM, Total Prevalent Cases of Very High TG (?500mg/dL), Both Sexes, Ages ?20 Years, N, 2013-2023 97

Table 22: 8MM, Age-Specific Total Prevalent Cases of Very High TG (?500mg/dL), Both Sexes, N (Row %), 2013 99

Table 23: 8MM, Sex-Specific Total Prevalent Cases of Very High TG (?500mg/dL), Ages ?20 Years, N (Row %), 2013 101

Table 24: Treatment Guidelines for Dyslipidemia 109

Table 25: Most Commonly Prescribed Drugs for Dyslipidemia by Class in the Global Markets, 2014 111

Table 26: Country Profile-US 116

Table 27: Country Profile-France 119

Table 28: Country Profile-Germany 122

Table 29: Country Profile-Italy 124

Table 30: Country Profile-Spain 126

Table 31: Country Profile-UK 128

Table 32: Country Profile-Japan 131

Table 33: Country Profile-China 133

Table 34: Leading Treatments for Dyslipidemia, 2014 138

Table 35: Statin Combination Therapies 140

Table 36: Product Profile-Lipitor 141

Table 37: Lipitor (atorvastatin) SWOT Analysis, 2014 143

Table 38: Global Sales Forecasts (USD m) for Lipitor (atorvastatin), 2013-2023 144

Table 39: Product Profile-Crestor (rosuvastatin) 146

Table 40: Crestor (rosuvastatin) SWOT Analysis, 2014 148

Table 41: Global Sales Forecasts (USD m) for Crestor (rosuvastatin), 2013-2023 149

Table 42: Product Profile-Zocor (simvastatin) 150

Table 43: Zocor (simvastatin) SWOT Analysis, 2014 152

Table 44: Global Sales Forecasts (USD m) for Zocor (simvastatin), 2013-2023 153

Table 45: Product Profile-Livalo (pitavastatin) 154

Table 46: Livalo (pitavastatin) SWOT Analysis, 2014 157

Table 47: Product Profile-Zetia (ezetimibe) 160

Table 48: Zetia (ezetimibe) SWOT Analysis, 2014 166

Table 49: Global Sales Forecasts (USD m) for Zetia (ezetimibe), 2013-2023 167

Table 50: Product Profile-Vytorin (simvastatin/ezetimibe) 168

Table 51: Vytorin (simvastatin/ezetimibe) SWOT Analysis, 2014 170

Table 52: Global Sales Forecasts (USD m) for Vytorin (simvastatin/ezetimibe), 2013-2023 171

Table 53: Product Profile-Liptruzet (atorvastatin/ezetimibe) 172

Table 54: Liptruzet (atorvastatin/ezetimibe) SWOT Analysis, 2014 174

Table 55: Global Sales Forecasts (USD m) for Liptruzet (atorvastatin/ezetimibe), 2013-2023 175

Table 56: Product Profile-Niaspan (niacin extended-release) 177

Table 57: Niaspan (niacin extended-release) SWOT Analysis, 2014 180

Table 58: Global Sales Forecasts (USD m) for Niaspan (niacin extended-release), 2013-2023 181

Table 59: Product Profile-Kynamro (mipomersen sodium) 183

Table 60: Kynamro-Induced Changes in Lipid Parameters from Akdim et al., 2010 184

Table 61: Kynamro-Induced Changes in Lipid Parameters from Raal et al., 2010 185

Table 62: Kynamro (mipomersen) SWOT Analysis, 2014 186

Table 63: Global Sales Forecasts (USD m) for Kynamro (mipomersen), 2013-2023 187

Table 64: Product Profile-Juxtapid (lomitapide) 189

Table 65: Juxtapid-Induced Dose-Responsive Changes in Lipid Parameters from Cuchel et al., 2007 190

Table 66: Juxtapid-Induced Changes in Lipid Parameters from Cuchel et al., 2013 191

Table 67: Juxtapid (lomitapide) SWOT Analysis, 2014 192

Table 68: Global Sales Forecasts (USD m) for Juxtapid (lomitapide), 2013-2023 193

Table 69: A Summary of the Therapeutic Properties of Fibrates* 194

Table 70: Product Profile-TriCor (fenofibrate) and Trilipix (fenofibric acid) 195

Table 71: TriCor/Trilipix (fenofibrate/fenofibric acid) SWOT Analysis, 2014 197

Table 72: Global Sales Forecasts (USD m) for TriCor/Trilipix (fenofibrate/fenofibric acid), 2013-2023 198

Table 73: Product Profile-Lovaza (omega-3 acid ethyl esters) 200

Table 74: Lovaza (omega-3 acid ethyl esters) SWOT Analysis, 2014 202

Table 75: Global Sales Forecasts (USD m) for Lovaza (omega-3 acid ethyl esters), 2013-2023 203

Table 76: Product Profile-Vascepa (icosapent ethyl) 205

Table 77: Vascepa (icosapent ethyl) SWOT Analysis, 2014 207

Table 78: Global Sales Forecasts (USD m) for Vascepa (icosapent ethyl), 2013-2023 208

Table 79: Product Profile-Epanova (omega-3 carboxylic acids) 209

Table 80: Epanova-Induced Changes in Blood Lipid Parameters from Kastelein et al., 2012 211

Table 81: Epanova-Induced Changes in Blood Lipid Parameters from Maki et al., 2013 211

Table 82: Epanova (omega-3 carboxylic acids) SWOT Analysis, 2014 212

Table 83: Global Sales Forecasts (USD m) for Epanova (omega-3 carboxylic acids), 2013-2023 213

Table 84: Product Profile-Welchol (colesevelam HCl) 215

Table 85: Welchol-Induced Changes in Blood Glucose and Lipid Parameters from Zieve et al., 2007 216

Table 86: Welchol (colesevelam HCl) SWOT Analysis, 2014 217

Table 87: Global Sales Forecasts (USD m) for Welchol (colesevelam HCl), 2013-2023 218

Table 88: Unmet Need and Opportunity in Dyslipidemia 220

Table 89: Comparison of Therapeutic Classes in Development for Dyslipidemia, 2014 236

Table 90: Product Profile-Alirocumab 240

Table 91: Alirocumab SWOT Analysis, 2014 245

Table 92: Global Sales Forecasts (USD m) for Alirocumab, 2013-2023 246

Table 93: Product Profile-Bococizumab 247

Table 94: Bococizumab SWOT Analysis, 2014 250

Table 95: Global Sales Forecasts (USD m) for Bococizumab, 2013-2023 251

Table 96: Product Profile-Evolocumab 253

Table 97: Phase III Clinical Trials of Evolocumab Reported by Amgen from Q4 2013-Q1 2014 255

Table 98: Evolocumab SWOT Analysis, 2014 259

Table 99: Global Sales Forecasts (USD ) for Evolocumab, 2013-2023 260

Table 100: Product Profile-Anacetrapib 262

Table 101: Anacetrapib SWOT Analysis, 2014 266

Table 102: Global Sales Forecasts (USD ) for Anacetrapib, 2013-2023 267

Table 103: Product Profile-Evacetrapib 269

Table 104: Evacetrapib SWOT Analysis, 2014 273

Table 105: Global Sales Forecasts (USD ) for Evacetrapib, 2013-2023 274

Table 106: Product Profile-TA-8995 (DEZ-001) 275

Table 107: Impact of Steady-State TA-8995 on CETP and Lipid Parameters from Ford et al., 2014 276

Table 108: TA-8995 SWOT Analysis, 2014 279

Table 109: Global Sales Forecasts (USD ) for TA-8995, 2013-2023 280

Table 110: Product Profile-CER-001 282

Table 111: CER-001 SWOT Analysis, 2014 285

Table 112: Global Sales Forecasts (USD ) for CER-001, 2013-2023 286

Table 113: Product Profile-ETC-1002 288

Table 114: ETC-1002/Ezetimibe Active Comparator Trial Results 290

Table 115: ETC-1002 SWOT Analysis, 2014 292

Table 116: Global Sales Forecasts (USD ) for ETC-1002, 2013-2023 293

Table 117: Dyslipidemia Drugs in Development, 2014 294

Table 118: Key Companies in the Dyslipidemia Market in the 8MM, 2014 298

Table 119: AbbVie�s Dyslipidemia Portfolio Assessment, 2014 303

Table 120: Aegerion�s Dyslipidemia Portfolio Assessment, 2014 305

Table 121: Amarin�s Dyslipidemia Portfolio Assessment, 2014 307

Table 122: Amgen�s Dyslipidemia Portfolio Assessment, 2014 309

Table 123: AstraZeneca�s Dyslipidemia Portfolio Assessment, 2014 312

Table 124: Cerenis� Dyslipidemia Portfolio Assessment, 2014 314

Table 125: Daiichi Sankyo�s Dyslipidemia Portfolio Assessment, 2014 316

Table 126: Dezima�s Dyslipidemia Portfolio Assessment, 2014 318

Table 127: Eli Lilly�s Dyslipidemia Portfolio Assessment, 2014 320

Table 128: Esperion�s Dyslipidemia Portfolio Assessment, 2014 323

Table 129: Genzyme�s Dyslipidemia Portfolio Assessment, 2014 325

Table 130: GlaxoSmithKline�s Dyslipidemia Portfolio Assessment, 2014 327

Table 131: Merck�s Dyslipidemia Portfolio Assessment, 2014 330

Table 132: Pfizer�s Dyslipidemia Portfolio Assessment, 2014 332

Table 133: Regeneron�s Dyslipidemia Portfolio Assessment, 2014 334

Table 134: Sanofi�s Dyslipidemia Portfolio Assessment, 2014 337

Table 135: Global Sales Forecasts (USD m) for Dyslipidemia, 2013-2023 342

Table 136: Dyslipidemia Market-Drivers and Barriers, 2014 348

Table 137: Sales Forecasts (USD ) for Dyslipidemia in the United States, 2013-2023 353

Table 138: Key Events Impacting Sales for Dyslipidemia in the US, 2014 356

Table 139: Dyslipidemia Market-US Drivers and Barriers, 2014 357

Table 140: Sales Forecast (USD m) for Dyslipidemia in the 5EU, 2013-2023 360

Table 141: Key Events Impacting Sales for Dyslipidemia in the 5EU, 2014 367

Table 142: Dyslipidemia Market-5EU Drivers and Barriers, 2014 368

Table 143: National Healthcare Authorities in the 5EU Nations 368

Table 144: National Public Health Initiatives in the 5EU Nations 369

Table 145: Governmental Drug Pricing Authorities in the 5EU Nations 370

Table 146: Sales Forecasts (USD ) for Dyslipidemia in Japan, 2013-2023 372

Table 147: Key Events Impacting Sales for Dyslipidemia in Japan, 2014 374

Table 148: Dyslipidemia Market-Japan Drivers and Barriers, 2014 375

Table 149: Sales Forecasts (USD ) for Dyslipidemia in China, 2013-2023 378

Table 150: Key Events Impacting Sales for Dyslipidemia in China, 2014 381

Table 151: Dyslipidemia Market-China Drivers and Barriers, 2014 381

Table 152: Key Launch Dates 422

Table 153: Key Patent Expiries 422

Table 154: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country 434

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AbbVie

Aegerion Pharmaceuticals, Inc.

Amarin

Amgen

AstraZeneca

Cerenis Therapeutics Inc.

Daiichi Sankyo

Dezima Pharma

Eli Lilly

Esperion Therapeutics, Inc.

Genzyme

GlaxoSmithKline

Merck & Co.

Pfizer

Regeneron Pharmaceuticals, Inc.

Sanofi


Related Products in vertical
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com